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1. Introduction 
In 1949 Hench & Kendall published the first report of a treatment that was to revolutionise 
the management of rheumatoid arthritis (RA) (Hench & Kendall, 1949) and indeed, much of 
medicine. Their work was based on the observation that RA seemed to improve in patients 
who were pregnant or jaundiced. The adrenal cortex extract they used contained the 
hormone 17-hydroxy-11-dehydrocorticosterone, and they set the scene for the use of 
glucocorticoid (GC) therapy in the management of RA. In the 62 years since that seminal 
publication, our knowledge of the mechanisms of action of GC has increased markedly. The 
extent of GC use has ebbed and flowed because of concerns about adverse effects and in the 
light of the subsequent discovery of new anti rheumatic agents, but nevertheless the role of 
GC in the clinic has endured and around 10 million new prescriptions for oral GC are 
written each year in the USA alone (Schäcke et al, 2002) 
In recent years the importance of GC in preventing long term joint erosions has been 
confirmed (Kirwan et al., 1995). Today they are seen as an important “disease modifying” 
agent in their own right and are recommended by the UK National Institute for Health and 
Clinical Excellence (NICE) for the early treatment of rheumatoid arthritis (Rudolph, 2009). 
Moreover, they remain an effective clinical tool for achieving short term control of disease 
flares especially in high doses administered intravenously. Their use in intra-articular 
injections is also a mainstay for targeting disease flares in particular joints and thus GC 
continue to form an important part of the therapeutic armoury of rheumatological practice 
(van Vollenhoven, 2009).  
The main clinical problem associated with the use of GC is the numerous adverse effects. 
The most serious of these include the development of glucose resistance or in some 
instances type 2 diabetes. Other important adverse effects include hypertension, 
osteoporosis, skin changes, sleep disturbance, weight gain and changes to body fat 
distribution (Schäcke et al., 2002). This wide spectrum of actions reflects the many 
physiological roles of endogenous GC.  
As our knowledge of the action of GC increases, we can begin to tackle the two key 
challenges that lie ahead. Firstly, how can the benefits of these drugs be utilised while 
minimising their many adverse effects. Secondly, is it possible to identify a distinct subset of 
patients with inflammatory disorders who are resistant to GC. Apart from RA, clinical GC 
resistance can be found in a range of inflammatory conditions including asthma, 
inflammatory bowel disease and uveitis (Barnes & Adcock, 2009). GC-resistant disease is the 
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cause of considerable morbidity, as affected individuals are subject both to the adverse 
sequelae of on-going inflammation, and the systemic adverse effects of GC. The mechanisms 
underlying this phenomenon are becoming more apparent and understanding and 
overcoming GC resistance in a subset of RA patients may offer further insight into the 
pathophysiology of RA itself.  
2. Glucocorticoid use in rheumatoid arthritis 
GC are still widely used in the management of RA and between 25-75% of patients with RA 
are treated more or less continuously with GC (Johannes et al., 2010). They are used in high 
doses (including intra-articular injection which provides a high dose to the synovium) to 
rapidly control acute disease flares. Moreover, the anti-inflammatory effects of lower dose 
GC can also be beneficial for a large number of patients especially when starting standard 
disease modifying anti-rheumatioc drugs (DMARDs) which often take weeks to months to 
have their full effect. Whether this anti-inflammatory effect persists in the long term over 
and above that achieved by standard DMARDs is a matter of debate.  
The most recently confirmed  role of GC is their use in preventing long term joint erosions 
as measured through radiological progression. In the last 10-15 years this observation 
(Kirwan et al., 2007) has put GC firmly back on the map as effective disease modifying 
agents in their own right. 
2.1 High dose short term therapy 
The use of high dose GC therapy to control life threatening complications of rheumatic 
diseases such as rheumatoid vasculitis is widespread. Intravenous methyprednisolone is 
often used in “pulsed therapy” at doses of around 1000mg. At these doses all GC receptors 
are saturated and there are undoubtedly non-genomic effects as discussed later in this 
chapter (Tyrrell & Baxter, 1995).  
The necessity of such high doses in clinical practice remains a matter for debate due to the 
lack of large randomized controlled trials in rheumatoid arthritis which specifically address 
this question. The practice has been inherited largely from success in managing life 
threatening systemic lupus erythematosus and from transplant rejection rescue. In the 
clinical setting however, such doses seem to be successful and this success is captured in 
small non controlled and retrospective trials (Jacobs et al., 2001; Weusten et al., 1993). These 
small trials also demonstrate that short term pulsed therapy is relatively safe but there 
remains the concern over significant infection from profound immunosupression. A review 
by Badsha et al in 2003 suggested that lower (but still high) doses may be just as effective 
(Badsha & Edwards, 2003). 
2.2 Anti-Inflammatory effects of low dose therapy 
GC therapy is often initiated shortly after diagnosis in RA usually in combination with 
disease modifying agents. Many patients find GC to be very effective in controlling their 
symptoms and continue the therapy long term. A recent Cochrane review confirmed the 
effectiveness of low dose (<15mg per day) GC therapy compared to traditional NSAIDs 
and placebo. It analysed 10 studies with 320 patients and the overall results showed an 
improvement in all parameters with GC therapy. These included pain scales, joint scores, 
morning stiffness, fatigue and improvement in acute phase reactant levels (Criswell et al., 
2000; Gotzsche & Johansen, 2004). The therapeutic benefit is much greater than that of 
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other anti-inflammatory treatments, with an effect size of about 1.25. However, these 
results do not seem to be sustained in most patients after 6 to 12 months. In practice some 
patients are unable to completely come off GC therapy as they experience a recurrence of 
symptoms. 
2.3 Role of low dose glucocorticoids in prevention of joint erosions 
The first report of the disease modifying effects of long term low dose glucocorticoids was in 
1995. The Arthritis and Rheumatism Council Low Dose Glucocorticoid Study was a double 
blind placebo controlled trial which studied the effects of 7.5mg of prednisolone (in addition 
to standard therapy for RA ) on radiographic joint erosions. The results showed a significant 
benefit in the prednsiolone group but no statistically significant difference in adverse events 
between treatment and placebo (Kirwan et al., 1995). This observation again confirms that 
low dose GC is relatively safe in clinical practice and in this case the risk versus harm 
balance clearly falls in favour of treatment with GC. 
There are now 14 randomised controlled trials included in a Cochrane meta-analysis 
(Kirwan et al., 2007) which concludes that low dose GC therapy in addition to standard 
therapy in rheumatoid arthritis significantly reduces the rate of joint erosions (Fig 1). The 
doses needed to achieve these effects are modest and hence associated with less adverse 
effects. Even in studies of patients not taking other conventional DMARDs alongside GC, 
the average reduction in the rate of joint progression was 70%. 
 
 
Fig. 1. Summary of data from Cochrane meta-analysis  (Kirwan et al., 2007) 
Subsequent analysis of longer term follow up data from some of these studies shows that 
the anti-erosive effects of GC persist several years after the treatment has been discontinued 
(Fig 2). In particular the data from the COBRA trial which compared sulphasalazine alone 
with combination sulphasalazine, methotrexate and a tapering dose of prednisolone showed 
anti-erosive benefits at 5 years in the GC group, long after the GC had been discontinued 
(Landew et al., 2002). The Uterecht trial (Johannes et al., 2006) which looked at the effects of 
10mg prednisolone in a DMARD naïve group of patients also demonstrated a significant 
reduction in radiological joint progression at 2 years which was sustained at 5 years (2 years 
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after discontinuation of the prednisolone). This continued benefit of GC in preventing joint 
erosions long after their anti-inflammatory benefits have subsided is noteworthy. There is 
increasingly an appreciation in the literature for several simultaneous pathogenic processes 
taking place in the RA joint. In particular joint erosions and synovitis seem to be two distinct 
processes and their apparent dissociation in the case of GC therapy is therefore not 
surprising (Kirwan, 2004). 
 
 
Fig. 2. X-ray progression after stopping trial therapy 
2.4 Adverse effects of glucocorticoids in rheumatology practice 
In 2007 Hoes et al published the EULAR evidence-based recommendations on the 
management of systemic GC therapy in rheumatic diseases (Hoes et al., 2007). The table of 
their key recommendations is reproduced below (Fig 3) but as part of their review process 
they quantified the incidence of reported adverse events in the glucocorticoid treated arms 
from 18 studies which included 963 patients taking 30mg or less of prednisolone (or 
equivalent) for the treatment of rheumatic diseases. The average dose across all studies was 
8mg of prednisolone and the mean duration of follow up was 19.6 months. The results (Fig 
4) are reported as adverse events per 100 patient years and provide an overview of the types 
of adverse events reported in GC use at these doses. (Not all these will actually be 
attributable to GC). 
An important point to note when considering cardiovascular and osteoporotic fracture risk 
in the context of GC use is the underlying risk posed by the inflammatory disease itself. It 
has been shown that chronic inflammatory conditions are associated with an increased 
fracture risk and bone mineral density loss (Cooper et al., 1995; Staa et al., 2006; Hoff et al., 
2007). Moreover, the increased cardiovascular risks associated RA and other inflammatory 
conditions are now very well established (Peters et al., 2010). Clearly the relationship 
between the beneficial effects of GC in controlling inflammation which, drives adverse 
events in these settings, and the GC contributions to the above risks are quite complex.  
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Proposition 
Strength of 
Recommendation 
(0-100 VAS) 
The adverse effects of GC therapy should be considered and discussed 
with the patient before GC therapy is started
92 
 This advice should be reinforced by giving information regarding 
GC management
93 
 If GC are to be used for a more prolonged period of time, a 
‘‘glucocorticoid card’’ is to be issued to every patient, with the date 
of commencement of treatment, the initial dosage and the 
subsequent reductions and maintenance regimens
79 
  
Initial dose, dose reduction and long-term dosing depend on the 
underlying rheumatic disease, disease activity, risk factors and individual 
responsiveness of the patient
86 
 Timing may be important, with respect to the circadian rhythm of 
both the disease and the natural secretion of GC
57 
  
When it is decided to start GC treatment, comorbidities and risk factors 
for adverse effects should be evaluated and treated where indicated; these 
include hypertension, diabetes, peptic ulcer, recent fractures, presence of 
cataract or glaucoma, presence of (chronic) infections, dyslipidaemia and 
comedication with non-steroidal anti inflammatory drugs
92 
  
For prolonged treatment, the GC dosage should be kept to a minimum, 
and a GC taper should be attempted in case of remission or low disease 
activity; the reasons to continue GC therapy should be regularly checked
86 
  
During treatment, patients should be monitored for body weight, blood 
pressure, peripheral oedema, cardiac insufficiency, serum lipids, blood 
and/or urine glucose and ocular pressure depending on individual 
patient’s risk, GC dose and duration
93 
  
If a patient is started on prednisone >7.5 mg daily and continues on 
prednisone for more than 3 months, calcium and vitamin D 
supplementation should be prescribed
100 
 Antiresorptive therapy with bisphosphonates to reduce the risk of 
GC-induced osteoporosis should be based on risk factors, including 
bone-mineral density measurement
93 
 
  
Patients treated with GC and concomitant non-steroidal anti-
inflammatory drugs should be given appropriate gastro-protective 
medication, such as proton pump inhibitors or misoprostol, or 
alternatively could switch to a cyclo-oxygenase-2 selective inhibitor
93 
 
  
All patients on GC therapy for longer than 1 month, who will undergo 
surgery, need perioperative management with adequate GC replacement 
to overcome potential adrenal Insufficiency
93 
  
GC during pregnancy have no additional risk for mother and child 87 
  
Children receiving GC should be checked regularly for linear growth and 
considered for growth-hormone replacement in case of growth impairment
93 
Fig. 3. Summary of EULAR recommendations for the use of GC in rheumatological practice. 
(VAS=visual analogue score) 
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Indeed a cohort study examining the interaction between GC therapy and cardiovascular 
risk in RA showed GC therapy to be associated with an increased risk only if patients were 
rheumatoid factor (RF) positive (Davis et al., 2007). In fact in RF negative patients GC were 
not associated with increased risk regardless of the cumulative dose and indeed showed a 
trend towards being protective.  
 
Type of Adverse Event Median:(25th-75th 
percentiles) 
AEs per 100 patient years 
Cardovascular 
(dyslipidemia, oedema, hypertension, heart failure) 
15 (3-28) 
Infectious (viral, bacterial, skin infections) 15 (3-15) 
Gastrointestinal (peptic ulcer, pancreatitis) 10 (4-20) 
Psychological and behavioural  
(minor mood disturbance, psychosis) 
9 (2-236) 
Endocrine and metabolic 
(glucose intolerance, diabetes, fat redistribution) 
7 (3-34) 
Dermatological (cutaneous atrophy, acne, hirsutism, alopecia) 5 (2-80) 
Musculoskeletal (osteoporosis, osteonecrosis, myopathy) 4 (3-9) 
Ophthalmological (glaucoma, cataract) 4 (0-5) 
Fig. 4. Reported adverse events in GC treated patients with rheumatological diseases. 
In summary, GC are widely used in the management of RA and rheumatologists have over 
60 years experience in their use. At low doses they act as to reduce the symptoms of RA in 
the first 6 to 12 months but in addition, their use early in the disease process substantially 
slows the progression of joint destruction and results in less disability in the long term. 
Remarkably this joint protective effect seems to be sustained years after GC are discontinued 
and for this reason GC can both be considered to be true “disease modifying” anti-
rheumatic drugs (Bijlsma et al., 2010) and to have some kind of effect on the underlying long 
term disease process. At higher doses they are effective in treating severe and life 
threatening flares of disease. Adverse effects remain a significant problem but in the balance 
of risk versus benefit, GC (especially at lower doses) can be considered relatively safe. The 
summary of the EULAR recommendations in GC use are reproduced below and are a useful 
tool for clinicians to refer to in their daily practice.  
3. Mechanism of action of GC 
A better understanding of the mechanisms of GC action is crucial for understanding how to 
utilise these drugs more effectively in the clinical setting while minimising their adverse 
effects. In general terms the mechanisms of action can be divided into genomic and non-
genomic. The genomic actions of GC are medicated through gene transcription and take 
hours to days to occur while the non-genomic actions are more rapid (Fig 5). 
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3.1 Genomic mechanisms  
GC have a lipophilic structure and low molecular mass. They therefore pass easily through 
the cell membrane and exert their effects mainly through binding with the glucocorticoid 
receptor (GCR) in the cytoplasm (Rhen & Cidlowski, 2005). There are two isoforms of the 
GCR, ǂ and ǃ. GCR-ǂ is the biologically active form of the receptor and mediates the 
intracellular effects of GC. GCR-ǃ is an alternativley spliced form which may act as 
dominant neagtive inhibitor of GC action (Lewis-Tuffin, 2006). Over expression of GCR-ǃ 
may be implictaed in GC resistance as will be discussed later in this chapter. 
The GCR-ǂ in the cytoplasm is associated with various heat shock proteins (HSPs) including 
HSP40, HSP56, HSP 70 and HSP90 (McLaughlin & Jackson, 2002) which are released when 
the receptor binds to GC After binding, the complex translocates to the neucleus where it 
exerts its effects on gene transcription (Davies et al., 2002). At the neucleus GCRs 
homodimerise and bind to GC response elements (GREs) in the promoter region of the 
target genes and lead to activation or inhbition of gene transcription. In addition the DNA 
bound GCR can also directly bind transcription co-activator molecules and exert further 
actions this way (Barnes, 2006). 
In activated inflammatory cells there is an additional route for GC action. This is because 
inflammatory stimuli ultimately lead to the activation of neuclear factor κB (NFκB) which 
binds to specific κB recognition sites on promoter regions of inflammatory genes in addition 
to coactivators such as cyclic AMP response element binding protein (CBP). The coactivators 
cause acetylation of core histones which leads to their unravelling and opens up the genes 
for transcription. Activated GCRs and the HSPs that are released when the GC binds to the 
receptor inhibit this effect directly by binding the coactivators and recruiting histone 
deacetylase (HDAC) 2 which inhibits acetylation (Rhen & Cidlowski, 2005). GC also switch 
on the transcription of certain genes including mitogen-activated protein (MAP) kinase 
phosphatase 1 (MKP1) hence inhibiting the MAP kinase pathway which is involved in 
proinflammatory gene transcription (Clark, 2003). The existence of this pathway has led to a 
search for ways of enhancing this GC effect, which would apply only in activated 
inflammatory cells and would therefore not be relevant to other body tissues, and hence 
would not contribute to adverse effects. 
3.2 Non-genomic mechanisms 
Some of the effects of GC occur within minutes of their administration especially at high 
intravenous doses (Croxtall et al., 2000). The mechanisms involved in mediating this rapid 
action are non-genomic as they are transcription independent. So far three such non-
genomic actions of GC have been described. The first involved the observation of the 
rapid reversal by dexamethasone of epidermal growth factor-stimulated activation of 
phospholipase A2. It is thought that this effect is medicated by chaperone molecules such 
as Src which are rapidly released from the GCR-GC complex on ligation (Croxtall et al., 
2000). 
Non-specific non-genomic effects are seen at very high doses of GC therapy and are thought 
to be due the saturation of all available GCRs in the cells at doses above 100mg perdnisolone 
or equivalent (Tyrrell & Baxter, 1995). At these doses it is thought that GC molecules 
dissolve into the membranes and alter proton leak hence influencing membrane transport 
(Buttgereit & Scheffold, 2002).  
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Fig. 5. Cellular action of glucocorticoids 
It is now thought that GC also have specific non-genomic effects that are mediated through 
membrane bound GCRs which are found in small numbers on human peripheral blood 
mononuclear cells (Bartholome et al., 2004). Moreover, stimulation of these cells in vitro by 
lipopolyscaharide (LPS) increases the percentage of membrane GCR expressing monocytes 
indicating an active upregulation of this process (Bartholome et al., 2004). Interestingly in 
patients with RA who have an activated immune system, the percentage memebrane GCR 
expressing monocytes is increased, in keeping with the in-vitro observations. These membrane 
expressed receptors are thought to be variants of the classical cytoplasmic GCRs (Löwenberg 
et al., 2007) and have recently been shown to also interact with the MAP kinase pathway 
(Strehl et al., 2011) Moreover, the engagement of these receptors is thought to inhibit T cell 
signalling by acting through downstream TCR associated signalling proteins lymphocyte-
specific tyrosine kinase (LCK) and FYN oncogene (Lowenberg et al., 2006). It is possible that 
memberane glucocorticoid receptors will prove to have therapeutic implications. 
3.3 Understanding adverse effects of GC therapy 
The functions of endogenous GC are numerous. It is estimated that GC influence the 
transcription of ~1% of the entire genome and 20% of genes expressed on human leukocytes 
through their direct effects on transcription and their interaction with coactivators and 
transcription factors (Galon et al., 2002; Goulding & Flower, 2001). These include effects on 
metabolism, homeostasis and immune function. Most of the therapeutic effects are mediated 
via repression of gene activation in pro-inflammatory pathways. However, only certain 
adverse effects result from repression of gene transcription such as suppression of the 
hypothalamic-pituitary-adrenal axis while others are mediated via activation of gene 
transcription as is the case with diabetes. In some instances such as osteoporosis, there may 
be a complex interaction between gene activation and repression and the exact mechanism 
remains unclear in many cases (Schäcke et al., 2002) (Fig 6). 
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Mechanism [X= Confirmed, (X)= 
Possible]
Adverse Effect 
Primary Targeted 
Molecule 
DNA Dependent 
DNA 
Independen
t 
  Activation 
Repressio
n
Repression 
Skin atrophy Type I collagen (X) 
 Type II collagen (X) (X) 
 Tenscin C (X) (X) 
 Sulfated 
glycosaminoglycans
(X) (X) 
  
Wound healing Pro-inflmmatory genes X 
 
Osteoporosis Osteoblast/osteocyte 
apoptosis
X  
 OPG-L X  
 OPG (X) (X) 
 Osteocalcin X  
 Type I collagen (X) 
 
Muscle atrophy Glutamine synthetase (X)  
 Ubiquitin-proteasome 
pathway 
(X)  
 
Glaucoma TIGR/MYOC gene 
product 
X  
 Fibronectin (X)  
 Type IV collagen (X)  
 Type I collagen (X)  
 
Psychiatric  5HT1A receptor X 
 
HPA 
suppression 
CRH X 
 POMC/ACTH X  
 
Diabetes 
Mellitus 
TAT X  
 AAT X  
 G6Pase X  
 PEPCK X  
 
Hypertension ǂENAC X  
 sgk X  
Fig. 6. Adverse effect associated proteins: regulation by GC and mechanisms. Reproduced 
from Schäcke et al, Pharmacology and therapeutics 96 (2002) 23-43 
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GC have a mixture of genomic and non-genomic therapeutic effects depending on the dosage 
used. Broadly speaking genomic effects occur at lower doses while non-genomic effects 
become relevant at higher doses with the combined effect of the two mechanisms accounting 
for the total effect of GC therapy (Fig 7). This has implications for therapeutics as at the lower 
doses not all the mechanisms are activated therefore the adverse effect profile may 
significantly differ. In essence low dose GC therapy is a very different treatment compared to 
high dose therapy both in terms of therapeutic effects and safety (Kirwan & Power, 2007). 
 
 
Fig. 7. Contribution of genomic and non genomic therapeutic effects of GC action is dose 
dependent. 
4. New drug development in glucocorticoid therapy 
There are several exciting developments in the world of GC therapy which aim to maintain 
the now well described benefits of this class of drugs whilst minimising adverse events. A 
better understanding of the mechanisms involved in GC action has made this goal a realistic 
one and there are already new licensed drugs on the market which are available for use in 
rheumatological practice. Broadly speaking there are two research strategies which are 
being pursued. The first approach aims to develop new GC analogues which can selectively 
reduce inflammation while minimising adverse effects (Kirwan & Power, 2007). This class of 
drugs are known as selective glucocorticoid receptor agonists or SEGRAs. This approach is 
based on the notion that the majority of therapeutic GC effects are due to the repression of 
gene transcription while the majority of the adverse effects are due to gene activation. 
Dissociating these two actions of GC is an attractive goal. The second approach utilises the 
improved understanding of the circadian HPA axis and its interaction with the 
inflammatory pathways and aims to develop new GC therapies that are better targeted to 
augment the natural diurnal variation. 
www.intechopen.com
 
The Clinical Role of Glucocorticoids in the Management of Rheumatoid Arthritis 13 
4.1 SEGRAs 
Dissociating the beneficial and adverse effects of GC was suggested over 10 years ago but 
has so far proved largely elusive. The first such compound was RU24858 which was 
described in 1997 by Vayssiere et al (Vayssière et al., 1997). Despite showing initial promise 
in dissociation of GC mediated gene activation and repression, the in-vivo effects were more 
disappointing and the drug did not make it into clinical trials (Belvisi et al., 2001). Other 
drugs such as A276575 have again shown promise but fared little better (Lin et al., 2002). 
The only SEGRA in clinical trials at the moment is ZK 245186 which is in Phase III trials for 
topical use post cateract surgery after initial results from animal models showed promise 
(Proksch et al., 2011). The Pahse II trail was concluded at the end of 2010 but results have not 
yet been released. The struggle to take SEGRAs from the bench to the bedside has been quite 
disappointing but not entirely surprising given the sheer number of biological mechanisms 
influenced by GC in vivo. 
4.2 Modified release glucocorticoids 
Modelling of the diurnal variation of the HPA axis and its effects on the secretion of 
systemic inflammatory cytokines in RA has been a novel approach which has yielded 
positive results. The cytokine IL-6 has been unequivocally shown to have a diurnal variation 
which causes an increase in serum concentrations during the night, before the natural 
increase in serum cortisol, and which reaches a peak at the time of morning waking (Perry et 
al., 2009). This has opened the door for the development of a modified release form of GC 
tablet which is taken at night and releases the active ingredients in the early hours of the 
morning (approximately 2 am) in order to target the peak in IL-6 levels (Kirwan, 2011). The 
rationale behind this approach suggests that better targeting of glucocorticoids within the 
HPA axis may produce better efficacy hence allowing clinicians to use smaller doses of GC. 
Indeed a multi-centre RCT comparing a modified release GC preparation with the 
equivalent prednisolone dose showed significant improvements in the duration of early 
morning stiffness in RA (Buttgereit et al., 2008). Interestingly, a recent study by Clarke et al. 
(Fig 8), which measured overnight cortisol concentrations as well as IL-6 in RA patients 
treated with modified release GC, showed the normal pre-treatment cortisol response to be 
suppressed in active RA and this suppression was reversed using the correctly timed 
modified release therapy with a corresponding decrease in IL-6 levels and clinical 
symptoms (Clarke et al., 2011). 
 
  
Fig. 8. Effects of modified release GC on 24 hour diurnal variation of systemic IL-6 and 
cortisol in RA patients 
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4.3 Other therapeutic advances 
Another interesting approach in the use of GC has been their use in combination with drugs 
that can amplify their intracellular effects at low doses. One approach looked at a 
preparation which combines low dose prednisolone in combination with dipyridamole 
(Kvien et al., 2008). This combination seemed to enhance the ability of GC to suppress the 
pro-inflammatory NFκB pathway (as mentioned in section 3.1) while sparing the gene-
transcription element of GC action which is associated with adverse effects. Other novel 
strategies involve targeting of the GC to the site of inflammation by encapsulating them in 
long-circulating liposomes (Schiffelers et al., 2006). This approach has shown promise in 
animal models of inflammatory arthritis but clinical studies are still lacking. These advances 
represent a potential new dawn for the use of GC in rheumatoid arthritis and have 
implications for a number of other inflammatory diseases. 
5. Glucocorticoid resistance 
5.1 The problem of glucocorticoid resistance 
GC resistance has been observed in the clinical setting for a long time and represents a 
challenge for clinicians as treatment requires larger doses of GC associated with an 
increased risk of adverse events. GC resistance may occur in a quarter to a third of RA 
patients. The emergence of this subgroup was first reported in a paper by Van 
Schaardenburg et al in 1995 (Van Schaardenburg et al., 1995). This study looked at elderly 
onset RA patients treated with oral prednisolone and a 30% discontinuation rate due to lack 
of efficacy was reported. Further confirmation of this phenomenon came in a study by 
Sliwinska-Stanczyk et al (Sliwinska-Stanczyk et al., 2007) who showed a 25% resistance rate 
in their 44 patients who had moderately active RA and who were not taking other disease 
modifying agents. This group went on to show that clinical GC resistance seemed to 
correlate with a failure of GC to adequately suppress in vitro peripheral blood mononuclear 
cell (PBMC) proliferation in the affected individuals.  
The problem of GC-resistance is not unique to RA and has been observed in a range of 
inflammatory conditions including ulcerative colitis (UC), asthma and uveitis (Creed & 
Probert, 2007; Lee et al., 2009;  Sousa et al., 2000;  Barnes & Adcock, 2009). The proportion of 
25-33% GC resistance seems to be preserved across the various diseases and the possible 
mechanisms underlying this are explored in the following sections. 
5.2 Genetic and acquired glucoccorticoid resistance 
There is a rare but well described familial or sporadic mutation of the GCR gene which 
results in GC resistance. This leads to activation of the HPA axis and compensatory 
elevations in circulating adrenocorticotropic hormone (ACTH) and cortisol. Patients with 
this disorder can develop adrenal hyperplasia as a result of the excess ACTH. Subsequent 
increase in mineralocorticoid and androgen release leads to a broad clinical spectrum whose 
manifestations depend on the severity of the disorder (Charmandari et al., 2008). This group 
of patients represents only a very small minority of GC resistance cases whilst acquired GC 
resistance in inflammatory conditions is quite common. In the last 10 years, more research 
effort has been focused on the problem of acquired GC resistance and several competing 
theories behind the underlying mechanism have emerged. 
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5.3 Glucocrticoid receptor β expression 
GCR-ǃ is an alternatively spliced form of the GC receptor and its over-expression has 
been linked with GC resistance in asthma, RA and inflammatory bowel disease (Hamid et 
al., 1999; Sousa et al., 2000; Kozaci et al., 2007; Orii et al., 2002). GCR-ǃ does not bind GC 
and in fact its natural ligand (if it has one) remains unknown (Lewis-Tuffin, 2006). 
However, it does compete with GCR-ǂ for the GRE binding sites on DNA, thus acting as a 
dominant negative inhibitor. Another anti-GC mechanism may be the disruption of active 
GCR-ǂ translocation to the nucleus since the down regulation of GCR-ǃ in the alveolar 
macrophages of patients with asthma leads to enhanced GCR-ǂ localization and a greater 
response to GC. Moreover, it has been shown that various pro-inflammatory cytokines 
can up regulate the expression of GCR-ǃ and this may explain why patients seem to 
develop clinical GC resistance with worsening of their inflammatory disease (Webster et 
al., 2001). 
5.4 Defects in histone acetylation 
The role of defective histone acetylation in acquired GC resistance has emerged principally 
from studies on patients with asthma and chronic obstructive pulmonary disease (COPD). 
As described previously, inflammatory stimuli ultimately lead to the activation of NFκB 
which binds to specific κB recognition sites on the promoter regions of inflammatory genes 
in addition coactivators which cause acetylation of core histones. This leads to their 
unravelling and opens up the genes for transcription. Activated GCRs inhibit this effect 
directly by binding the coactivators and recruiting histone deacetylase (HDAC) 2 which 
reverses the acetylation (Rhen & Cidlowski, 2005). GCRs themselves become acetylated 
upon ligand binding to allow them to bind GREs and can be targeted directly by HDAC2.  
HDAC2 activity has been shown to be reduced in alveolar macrophages of GC resistant 
asthma patients and patients with COPD (Ito et al., 2005; Hew et al., 2006). This reduced 
activity is thought to be secondary to the oxidative stress resulting from smoking 
(Rahman & Adcock, 2006). Smoking and obesity, both causes of oxaditive stress, are both 
risk factors for developing rheumatoid arthritis (Symmons et al., 1997). In COPD it has 
been shown that low dose oral theophylline can reverse GC resistance by restoring 
HDAC2 activity (Ito et al., 2005). This effect is independent of phosphodiesterase 
inhibition and is mediated via the selective inhibition phospho-inositide-3-kinase-δ 
(PI3Kδ). This is an enzyme which is activated by oxidative stress in patients with COPD 
(To et al., 2010). This pathway has not been studied in rheumatoid arthritis and presents a 
novel way of reversing GC resistance. 
5.5 T Helper-17 cells and glucocorticoid resistance 
T helper (Th) cells differentiate into distinct phenotypes under the influence of the 
inflammatory cytokine milieu which is largely dictated by cytokines released from 
monocyte derived macrophages. IL-17 producing T-helper cells (TH-17 cells) have recently 
been identified as a distinct pro-inflammatory T-helper subset and their role in various 
autoimmune processes including RA (Kirkham et al., 2006), multiple sclerosis (Matusevicius 
et al., 1999), psoriasis and inflammatory bowel disease (Duerr, 2006) is becoming more 
apparent. They seem to have a reciprocal relationship with regulatory IL-10 secreting T 
helper cells (McGeachy, 2007) and drive an inflammatory response which is dominated by 
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neutrophils (Miossec et al., 2009). There is increasing evidence to suggest they play a role in 
GC resistance in a variety of inflammatory diseases. 
The earliest reports of TH-17 cell involvement in GC resistance emerged from the asthma 
research community. McKinley et al. showed in a mouse model of asthma that naive T cells 
which were polarized to the TH-17 phenotype during differentiation (by adding IL-23, IL-6 
and TGF-ǃ in vitro) were less sensitive to dexamethasone compared to cells which  
differentiated to the TH-2 phenotype (McKinley et al., 2008). Subsequent work has shown an 
expanded TH-17 subset within PBMC cultures of patients with UC and uveitis (Lee et al., 
2009; Lee et al., 2007). The data from the uveitis and UC studies seems to suggest that the 
TH-17 phenotype is inherently GC resistant when tested using in-vitro stimulation assays. It 
seems that their number is expanded in patients with clinical GC resistance.  
 
 
Fig. 9. The proposed model for GC resistance. Monocyte derived macrophages influence T 
helper cell phenotype differentiation through various cytokines. The balance of pro-
inflammatory TH-17 cells and induced regulatory iTRegs alters the balance of IL-17, which 
increases GCR-ǃ expression and hence reduces response to GC, and IL-10, which increases 
GCR-ǂ expression and hence increases responsiveness to GC. The balance between these 
cytokines determines the balance between GC resistance and GC responsiveness. 
Increases
Increases 
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Other work in this area has shown higher levels of IL-17 mRNA in the bronchial biopsies of 
asthmatic patients compared to controls with increased expression of GCR-ǃ in response to 
IL-17. Dexamethasone was unable to decrease IL-17 induced IL-6 expression in these 
asthmatic patients (Vazquez-Tello et al., 2010). Conversely, the synthetic GC dexamethasone 
(Dex) normally induces the anti-inflammatory cytokine IL-10 in Th cells, and a deficiency in 
IL-10 up regulation in response to GC has been demonstrated in GC-resistant asthma 
(Xystrakis, 2005). Importantly IL-10 has been shown to enhance expression of GCR-ǂ 
(Xystrakis, 2005). Very little work has been carried out in this field in the context of RA but 
these findings suggest that a disturbed balance of T cell derived cytokines may be causing 
GC resistance by altering the balance of GCR subtype expression.  
5.6 A unifying model for glucocorticoid resistance 
The emerging concept is that the human GC-resistant phenotype is disease independent, 
and observations of immune responses in GC-resistant individuals across medical 
specialities strongly supports this (Barnes & Adcock 2009; Schewitz et al., 2009; Norman & 
Hearing, 2002). Moreover, the data suggests that T helper cell responses in GC-resistant 
individuals are biased against IL-10 and in favour of IL-17. Importantly, there is also 
evidence that such a cytokine profile may be instrumental in regulating the ratio of 
glucocorticoid receptor (GCR) isoforms. IL-10 has been shown to enhance expression of 
GCR-ǂ (Xystrakis, 2005), which augments GC-responses (Lewis-Tuffin, 2006), and  IL-17 
upregulates the level of GCR-ǃ (Vazquez-Tello et al., 2010), which attenuates GC-responses. 
Consistent with this, PBMCs from GC-resistant patients with RA express higher levels of 
GCR-ǃ (Kozaci et al., 2007) as do bronchoalveolar lavage washings from patients with GC-
resistant asthma (Vazquez-Tello et al., 2010). As mentioned earlier, monocyte derived 
macrophages and dendritic cells have a huge influence on T helper phenotype 
differentiation and their precise role in this model requires further research. Macrophages 
may well be the master regulators of this GC-resistant phenotype through their influencing 
of the T helper cells (Fig 9). 
It is interesting to note that there seems to be no resistance to the action of GC in terms of 
adverse effects. The most likely reason for this is that adverse effects are predominantly 
mediated by the excess activation of the transcription pathways which mediate the 
physiological role of GC action. Therefore administered exogenous GC potentially acts on 
all cells while the anti-inflammatory effects of GC are only mediated via their action on 
activated pro-inflammatory cells. Thus if these pro-inflammatory cells become GC resistant, 
GC resistant inflammation will occur alongside GC mediated adverse events. One key 
weakness of this model is that it does not take into account the important findings relating 
to histone acetylation which Barnes and colleagues have elucidated over the last 20 years 
and it would be interesting to study the effects of T helper derived cytokines on HDAC2 
expression. 
6. Conclusions 
Glucocorticoids have become an even more important therapeutic intervention in 
rheumatoid arthritis both for the control of acute disease flares and for the long term 
prevention of joint erosions. A better understanding of their mechanisms of action has 
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begun to address the two key challenges which limit their use: developing better targeted 
GCs which achieve clinical benefit while minimising adverse effects, and reversing GC 
resistance. There is likely to be progress on both fronts over the next few years. 
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